Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02629159




Registration number
NCT02629159
Ethics application status
Date submitted
10/12/2015
Date registered
14/12/2015
Date last updated
24/04/2023

Titles & IDs
Public title
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
Scientific title
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
Secondary ID [1] 0 0
2022-501017-31-00
Secondary ID [2] 0 0
M14-465
Universal Trial Number (UTN)
Trial acronym
SELECT-COMPARE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo for Adalimumab
Treatment: Drugs - Adalimumab
Treatment: Drugs - Placebo for Upadacitinib
Treatment: Drugs - Upadacitinib

Placebo Comparator: Placebo followed by ABT-494 - Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a = 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).
Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2.

Active Comparator: Adalimumab - Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a = 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] = 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.
Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2.

Experimental: Upadacitinib - Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a = 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI = 10) were to be switched to 40 mg adalimumab eow until Week 48.
Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2.


Treatment: Drugs: Placebo for Adalimumab
Administered by subcutaneous injection once every other week

Treatment: Drugs: Adalimumab
Administered by subcutaneous injection once every other week

Treatment: Drugs: Placebo for Upadacitinib
Tablets taken orally once a day

Treatment: Drugs: Upadacitinib
Tablets taken orally once a day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Timepoint [1] 0 0
Baseline and Week 12
Primary outcome [2] 0 0
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12
Timepoint [2] 0 0
Week 12
Secondary outcome [1] 0 0
Change From Baseline in DAS28 (CRP) at Week 12
Timepoint [1] 0 0
Baseline and Week 12
Secondary outcome [2] 0 0
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26
Timepoint [2] 0 0
Baseline and Week 26
Secondary outcome [3] 0 0
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
Timepoint [3] 0 0
Baseline and Week 12
Secondary outcome [4] 0 0
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Timepoint [4] 0 0
Baseline and Week 12
Secondary outcome [5] 0 0
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
Timepoint [5] 0 0
Baseline and Week 12
Secondary outcome [6] 0 0
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
Timepoint [6] 0 0
Week 12
Secondary outcome [7] 0 0
Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12
Timepoint [7] 0 0
Week 12
Secondary outcome [8] 0 0
Change From Baseline in Duration of Morning Stiffness at Week 12
Timepoint [8] 0 0
Baseline and Week 12
Secondary outcome [9] 0 0
Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
Timepoint [9] 0 0
Baseline and Week 12
Secondary outcome [10] 0 0
Change From Baseline in Patient's Assessment of Pain at Week 12
Timepoint [10] 0 0
Baseline and Week 12
Secondary outcome [11] 0 0
Percentage of Participants With No Radiographic Progression at Week 26
Timepoint [11] 0 0
Baseline and Week 26
Secondary outcome [12] 0 0
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Timepoint [12] 0 0
Baseline and Week 12

Eligibility
Key inclusion criteria
- Adult male or female, at least 18 years old.

- Diagnosis of RA for greater than or equal to 3 months.

- Subjects must have been on oral or parenteral methotrexate (MTX) therapy greater than
or equal to 3 months and on a stable prescription of greater than or equal to 15 to 25
mg/week (or greater than or equal to 10 mg/week in subjects intolerant of MTX at doses
greater than or equal to 12.5 mg/week) for at least 4 weeks prior to the first dose of
study drug. In addition all subjects should take a dietary supplement of folic acid or
folinic acid throughout the study participation.

- Meets the following minimum disease activity criteria: greater than or equal to 6
swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints
(based on 68 joint counts) at Screening and Baseline Visits.

- At least one of the following at Screening: greater than or equal to 3 bone erosions
on x-ray OR greater than or equal to 1 bone erosion and a positive rheumatoid factor
OR greater than or equal to 1 bone erosion and a positive anti-cyclic citrullinated
peptide autoantibodies.

- Subjects with prior exposure to only one biological disease-modifying anti-rheumatic
drugs (bDMARD) (except adalimumab) may be enrolled (up to 20% of total study
population) if they have documented evidence of intolerance to the bDMARD or limited
exposure (less than 3 months), but required washout periods need to be satisfied.

- Except for MTX, subject must have discontinued all conventional synthetic
disease-modifying anti-rheumatic drugs (csDMARDs).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
tofacitinib, baricitinib, and filgotinib).

- Subjects who have been exposed to adalimumab or who are considered inadequate
responders to bDMARD therapy as determined by the Investigator.

- History of inflammatory joint disease other than RA. History of secondary Sjogren's
Syndrome is permitted.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/09/2027
Actual
Sample size
Target
Accrual to date
Final
1629
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital /ID# 144857 - Camperdown
Recruitment hospital [2] 0 0
Emeritus Research /ID# 142848 - Camberwell
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3124 - Camberwell
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Mississippi
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New Mexico
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
West Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Argentina
State/province [29] 0 0
Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Cordoba
Country [31] 0 0
Argentina
State/province [31] 0 0
Rosario, Santa FE
Country [32] 0 0
Argentina
State/province [32] 0 0
Salta
Country [33] 0 0
Argentina
State/province [33] 0 0
San Fernando
Country [34] 0 0
Argentina
State/province [34] 0 0
San Miguel de Tucuman
Country [35] 0 0
Argentina
State/province [35] 0 0
Santa Fe
Country [36] 0 0
Austria
State/province [36] 0 0
Graz
Country [37] 0 0
Belarus
State/province [37] 0 0
Minsk
Country [38] 0 0
Belgium
State/province [38] 0 0
Bruxelles-Capitale
Country [39] 0 0
Belgium
State/province [39] 0 0
Hainaut
Country [40] 0 0
Belgium
State/province [40] 0 0
Liege
Country [41] 0 0
Belgium
State/province [41] 0 0
Oost-Vlaanderen
Country [42] 0 0
Belgium
State/province [42] 0 0
Mons
Country [43] 0 0
Bosnia and Herzegovina
State/province [43] 0 0
Republika Srpska
Country [44] 0 0
Bosnia and Herzegovina
State/province [44] 0 0
Sarajevo
Country [45] 0 0
Brazil
State/province [45] 0 0
Goias
Country [46] 0 0
Brazil
State/province [46] 0 0
Minas Gerais
Country [47] 0 0
Brazil
State/province [47] 0 0
Parana
Country [48] 0 0
Brazil
State/province [48] 0 0
Rio Grande Do Sul
Country [49] 0 0
Brazil
State/province [49] 0 0
Sao Paulo
Country [50] 0 0
Brazil
State/province [50] 0 0
Rio de Janeiro
Country [51] 0 0
Bulgaria
State/province [51] 0 0
Plovdiv
Country [52] 0 0
Bulgaria
State/province [52] 0 0
Sofia
Country [53] 0 0
Canada
State/province [53] 0 0
Manitoba
Country [54] 0 0
Canada
State/province [54] 0 0
Newfoundland and Labrador
Country [55] 0 0
Canada
State/province [55] 0 0
Ontario
Country [56] 0 0
Canada
State/province [56] 0 0
Quebec
Country [57] 0 0
Chile
State/province [57] 0 0
Araucania
Country [58] 0 0
Chile
State/province [58] 0 0
Concepcion
Country [59] 0 0
Chile
State/province [59] 0 0
Osorno
Country [60] 0 0
Chile
State/province [60] 0 0
Providencia-santiago
Country [61] 0 0
Chile
State/province [61] 0 0
Puerto Varas
Country [62] 0 0
Chile
State/province [62] 0 0
Santiago
Country [63] 0 0
Chile
State/province [63] 0 0
Temuco
Country [64] 0 0
Chile
State/province [64] 0 0
Vina Del Mar
Country [65] 0 0
Colombia
State/province [65] 0 0
Cundinamarca
Country [66] 0 0
Colombia
State/province [66] 0 0
Barranquilla
Country [67] 0 0
Colombia
State/province [67] 0 0
Bogota DC
Country [68] 0 0
Colombia
State/province [68] 0 0
Bogota
Country [69] 0 0
Colombia
State/province [69] 0 0
Bucaramanga
Country [70] 0 0
Colombia
State/province [70] 0 0
Medellín
Country [71] 0 0
Croatia
State/province [71] 0 0
Primorsko-goranska Zupanija
Country [72] 0 0
Croatia
State/province [72] 0 0
Split
Country [73] 0 0
Croatia
State/province [73] 0 0
Zagreb
Country [74] 0 0
Czechia
State/province [74] 0 0
Moravskoslezsky Kraj
Country [75] 0 0
Czechia
State/province [75] 0 0
Olomoucky Kraj
Country [76] 0 0
Czechia
State/province [76] 0 0
Praha 2
Country [77] 0 0
Czechia
State/province [77] 0 0
Praha 4
Country [78] 0 0
Czechia
State/province [78] 0 0
Brno
Country [79] 0 0
Czechia
State/province [79] 0 0
Bruntál
Country [80] 0 0
Czechia
State/province [80] 0 0
Kladno
Country [81] 0 0
Czechia
State/province [81] 0 0
Ostrava
Country [82] 0 0
Czechia
State/province [82] 0 0
Pardubice
Country [83] 0 0
Denmark
State/province [83] 0 0
Midtjylland
Country [84] 0 0
Denmark
State/province [84] 0 0
Silkeborg
Country [85] 0 0
Estonia
State/province [85] 0 0
Harjumaa
Country [86] 0 0
Estonia
State/province [86] 0 0
Tartumaa
Country [87] 0 0
Estonia
State/province [87] 0 0
Pärnu
Country [88] 0 0
Estonia
State/province [88] 0 0
Tallinn
Country [89] 0 0
France
State/province [89] 0 0
Haute-Garonne
Country [90] 0 0
France
State/province [90] 0 0
Hauts-de-France
Country [91] 0 0
France
State/province [91] 0 0
Herault
Country [92] 0 0
France
State/province [92] 0 0
Bordeaux
Country [93] 0 0
France
State/province [93] 0 0
Caen
Country [94] 0 0
France
State/province [94] 0 0
Clermont Ferrand
Country [95] 0 0
France
State/province [95] 0 0
Marseille
Country [96] 0 0
France
State/province [96] 0 0
Paris
Country [97] 0 0
France
State/province [97] 0 0
Rennes
Country [98] 0 0
France
State/province [98] 0 0
Strasbourg
Country [99] 0 0
Germany
State/province [99] 0 0
Nordrhein-Westfalen
Country [100] 0 0
Germany
State/province [100] 0 0
Schleswig-Holstein
Country [101] 0 0
Germany
State/province [101] 0 0
Chemnitz
Country [102] 0 0
Germany
State/province [102] 0 0
Hamburg
Country [103] 0 0
Germany
State/province [103] 0 0
Munich
Country [104] 0 0
Greece
State/province [104] 0 0
Attiki
Country [105] 0 0
Greece
State/province [105] 0 0
Athens
Country [106] 0 0
Hong Kong
State/province [106] 0 0
Hong Kong
Country [107] 0 0
Hong Kong
State/province [107] 0 0
Tuen Mun
Country [108] 0 0
Hungary
State/province [108] 0 0
Borsod-Abauj-Zemplen
Country [109] 0 0
Hungary
State/province [109] 0 0
Pest
Country [110] 0 0
Hungary
State/province [110] 0 0
Vas
Country [111] 0 0
Hungary
State/province [111] 0 0
Veszprem
Country [112] 0 0
Hungary
State/province [112] 0 0
Budapest
Country [113] 0 0
Hungary
State/province [113] 0 0
Debrecen
Country [114] 0 0
Hungary
State/province [114] 0 0
Heviz
Country [115] 0 0
Hungary
State/province [115] 0 0
Kiskunhalas
Country [116] 0 0
Hungary
State/province [116] 0 0
Kistarcsa
Country [117] 0 0
Ireland
State/province [117] 0 0
Dublin
Country [118] 0 0
Israel
State/province [118] 0 0
Tel-Aviv
Country [119] 0 0
Israel
State/province [119] 0 0
Haifa
Country [120] 0 0
Israel
State/province [120] 0 0
Ramat Gan
Country [121] 0 0
Italy
State/province [121] 0 0
Milano
Country [122] 0 0
Italy
State/province [122] 0 0
Piemonte
Country [123] 0 0
Italy
State/province [123] 0 0
Milan
Country [124] 0 0
Italy
State/province [124] 0 0
Verona
Country [125] 0 0
Kazakhstan
State/province [125] 0 0
Astana
Country [126] 0 0
Kazakhstan
State/province [126] 0 0
Karaganda
Country [127] 0 0
Kazakhstan
State/province [127] 0 0
Semey
Country [128] 0 0
Kazakhstan
State/province [128] 0 0
Shymkent
Country [129] 0 0
Korea, Republic of
State/province [129] 0 0
Daegu Gwang Yeogsi
Country [130] 0 0
Korea, Republic of
State/province [130] 0 0
Daejeon Gwang Yeogsi
Country [131] 0 0
Korea, Republic of
State/province [131] 0 0
Incheon Gwang Yeogsi
Country [132] 0 0
Korea, Republic of
State/province [132] 0 0
Jeonranamdo
Country [133] 0 0
Korea, Republic of
State/province [133] 0 0
Seoul Teugbyeolsi
Country [134] 0 0
Korea, Republic of
State/province [134] 0 0
Daegu
Country [135] 0 0
Korea, Republic of
State/province [135] 0 0
Seoul
Country [136] 0 0
Latvia
State/province [136] 0 0
Adazi
Country [137] 0 0
Latvia
State/province [137] 0 0
Daugavpils
Country [138] 0 0
Latvia
State/province [138] 0 0
Liepaja
Country [139] 0 0
Latvia
State/province [139] 0 0
Riga
Country [140] 0 0
Lithuania
State/province [140] 0 0
Kaunas
Country [141] 0 0
Lithuania
State/province [141] 0 0
Vilnius
Country [142] 0 0
Malaysia
State/province [142] 0 0
Kelantan
Country [143] 0 0
Malaysia
State/province [143] 0 0
Batu Caves
Country [144] 0 0
Malaysia
State/province [144] 0 0
Kuching
Country [145] 0 0
Malaysia
State/province [145] 0 0
Putrajaya
Country [146] 0 0
Malaysia
State/province [146] 0 0
Seremban
Country [147] 0 0
Mexico
State/province [147] 0 0
Ciudad De Mexico
Country [148] 0 0
Mexico
State/province [148] 0 0
Nuevo Leon
Country [149] 0 0
Mexico
State/province [149] 0 0
Chihuahua
Country [150] 0 0
Mexico
State/province [150] 0 0
Mexico City
Country [151] 0 0
Mexico
State/province [151] 0 0
Mérida
Country [152] 0 0
New Zealand
State/province [152] 0 0
Waikato
Country [153] 0 0
New Zealand
State/province [153] 0 0
Nelson
Country [154] 0 0
New Zealand
State/province [154] 0 0
Timaru
Country [155] 0 0
Poland
State/province [155] 0 0
Dolnoslaskie
Country [156] 0 0
Poland
State/province [156] 0 0
Kujawsko-pomorskie
Country [157] 0 0
Poland
State/province [157] 0 0
Lubelskie
Country [158] 0 0
Poland
State/province [158] 0 0
Malopolskie
Country [159] 0 0
Poland
State/province [159] 0 0
Mazowieckie
Country [160] 0 0
Poland
State/province [160] 0 0
Podlaskie
Country [161] 0 0
Poland
State/province [161] 0 0
Pomorskie
Country [162] 0 0
Poland
State/province [162] 0 0
Slaskie
Country [163] 0 0
Poland
State/province [163] 0 0
Bialystok
Country [164] 0 0
Poland
State/province [164] 0 0
Poznan
Country [165] 0 0
Poland
State/province [165] 0 0
Warsaw
Country [166] 0 0
Portugal
State/province [166] 0 0
Lisboa
Country [167] 0 0
Portugal
State/province [167] 0 0
Porto
Country [168] 0 0
Portugal
State/province [168] 0 0
Braga
Country [169] 0 0
Portugal
State/province [169] 0 0
Lisbon
Country [170] 0 0
Portugal
State/province [170] 0 0
Viana Do Castelo
Country [171] 0 0
Puerto Rico
State/province [171] 0 0
Ponce
Country [172] 0 0
Puerto Rico
State/province [172] 0 0
San Juan
Country [173] 0 0
Romania
State/province [173] 0 0
Bucuresti
Country [174] 0 0
Romania
State/province [174] 0 0
Iasi
Country [175] 0 0
Romania
State/province [175] 0 0
Oradea
Country [176] 0 0
Russian Federation
State/province [176] 0 0
Moskva
Country [177] 0 0
Russian Federation
State/province [177] 0 0
Permskiy Kray
Country [178] 0 0
Russian Federation
State/province [178] 0 0
Stavropol Skiy Kray
Country [179] 0 0
Russian Federation
State/province [179] 0 0
Tatarstan, Respublika
Country [180] 0 0
Russian Federation
State/province [180] 0 0
Tverskaya Oblast
Country [181] 0 0
Russian Federation
State/province [181] 0 0
Ivanovo
Country [182] 0 0
Russian Federation
State/province [182] 0 0
Moscow
Country [183] 0 0
Russian Federation
State/province [183] 0 0
Nizhnij Novgorod
Country [184] 0 0
Russian Federation
State/province [184] 0 0
Orenburg
Country [185] 0 0
Russian Federation
State/province [185] 0 0
Ryazan
Country [186] 0 0
Russian Federation
State/province [186] 0 0
St. Petersburg
Country [187] 0 0
Russian Federation
State/province [187] 0 0
UFA
Country [188] 0 0
Russian Federation
State/province [188] 0 0
Ulyanovsk
Country [189] 0 0
Serbia
State/province [189] 0 0
Beograd
Country [190] 0 0
Serbia
State/province [190] 0 0
Vojvodina
Country [191] 0 0
Slovakia
State/province [191] 0 0
Martin
Country [192] 0 0
Slovakia
State/province [192] 0 0
Nové Mesto Nad Váhom
Country [193] 0 0
Slovakia
State/province [193] 0 0
Partizanske
Country [194] 0 0
Slovakia
State/province [194] 0 0
Pieštany
Country [195] 0 0
Slovakia
State/province [195] 0 0
Rimavska Sobota
Country [196] 0 0
Slovakia
State/province [196] 0 0
Sabinov
Country [197] 0 0
Slovakia
State/province [197] 0 0
Stará Lubovna
Country [198] 0 0
Slovakia
State/province [198] 0 0
Topolcany
Country [199] 0 0
Slovakia
State/province [199] 0 0
Zvolen
Country [200] 0 0
South Africa
State/province [200] 0 0
Eastern Cape
Country [201] 0 0
South Africa
State/province [201] 0 0
Gauteng
Country [202] 0 0
South Africa
State/province [202] 0 0
Kwazulu-Natal
Country [203] 0 0
South Africa
State/province [203] 0 0
Western Cape
Country [204] 0 0
Spain
State/province [204] 0 0
Cantabria
Country [205] 0 0
Spain
State/province [205] 0 0
A Coruna
Country [206] 0 0
Spain
State/province [206] 0 0
Cordoba
Country [207] 0 0
Spain
State/province [207] 0 0
Santiago de Compostela
Country [208] 0 0
Taiwan
State/province [208] 0 0
Taichung
Country [209] 0 0
Taiwan
State/province [209] 0 0
Taipei
Country [210] 0 0
Taiwan
State/province [210] 0 0
Kaohsiung
Country [211] 0 0
Taiwan
State/province [211] 0 0
New Taipei City
Country [212] 0 0
Taiwan
State/province [212] 0 0
Taichung City
Country [213] 0 0
Taiwan
State/province [213] 0 0
Taipei City
Country [214] 0 0
Taiwan
State/province [214] 0 0
Taoyuan City
Country [215] 0 0
Turkey
State/province [215] 0 0
Cerrahpasa
Country [216] 0 0
Turkey
State/province [216] 0 0
Istanbul
Country [217] 0 0
Turkey
State/province [217] 0 0
Izmir
Country [218] 0 0
Ukraine
State/province [218] 0 0
Kyiv
Country [219] 0 0
Ukraine
State/province [219] 0 0
Lvivska Oblast
Country [220] 0 0
Ukraine
State/province [220] 0 0
Vinnytska Oblast
Country [221] 0 0
Ukraine
State/province [221] 0 0
Ivano-frankivsk
Country [222] 0 0
Ukraine
State/province [222] 0 0
Kiev
Country [223] 0 0
Ukraine
State/province [223] 0 0
Lviv
Country [224] 0 0
Ukraine
State/province [224] 0 0
Odesa
Country [225] 0 0
Ukraine
State/province [225] 0 0
Zaporizhia
Country [226] 0 0
United Kingdom
State/province [226] 0 0
London, City Of
Country [227] 0 0
United Kingdom
State/province [227] 0 0
Portsmouth
Country [228] 0 0
United Kingdom
State/province [228] 0 0
Warrington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to assess efficacy, including inhibition of radiographic
progression, and safety with upadacitinib versus placebo and versus an active comparator,
adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who
are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02629159
Trial related presentations / publications
Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28.
Public notes

Contacts
Principal investigator
Name 0 0
AbbVie Inc.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02629159